News
Johnson & Johnson announces a $2 billion North Carolina manufacturing expansion as part of a broader U.S. onshore ...
12h
Benzinga on MSNJ&J To Invest $2B In North Carolina As Trump Drug Tariff Threats Push Pharma To Expand U.S. Footprint
Johnson & Johnson said Thursday it will invest $2 billion in North Carolina to expand U.S. manufacturing, according to ...
12h
TipRanks on MSNEli Lilly’s Promising Cancer Therapy Study: A Potential Game-Changer?
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is conducting a clinical ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.
Longer-term data show that donanemab’s cognitive benefits continue to grow over time, and earlier initiation reduces the risk for progression, with no new safety signals.
Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for the long term. In a report released on August 13, Seamus Fernandez from Guggenheim maintained a Buy rating on Eli Lilly and ...
Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...
In a study published in Molecular Metabolism, University of Michigan researchers have shown that a specific population of ...
As the world’s population ages at an unprecedented rate, the field of longevity research is surging to the forefront of ...
Sure, nobody goes around boasting, "We're Number Two!" But in certain circumstances, coming in second has its advantages.
In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing ...
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results